KNSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KNSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kiniksa Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Kiniksa Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
During the past 8 years, the highest Piotroski F-Score of Kiniksa Pharmaceuticals was 7. The lowest was 1. And the median was 4.
The historical data trend for Kiniksa Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | 2.00 | 5.00 | 7.00 | 2.00 |
Kiniksa Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Piotroski F-Score | Get a 7-Day Free Trial | 7.00 | 6.00 | 3.00 | 2.00 | 3.00 |
For the Biotechnology subindustry, Kiniksa Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiniksa Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar24) TTM: | Last Year (Mar23) TTM: |
Net Income was 14.972 + -13.855 + 25.237 + -17.704 = $8.7 Mil. Cash Flow from Operations was -3.743 + 16.986 + 4.325 + 3.987 = $21.6 Mil. Revenue was 71.473 + 67.046 + 83.395 + 79.858 = $301.8 Mil. Gross Profit was 49.788 + 40.647 + 113.396 + 48.474 = $252.3 Mil. Average Total Assets from the begining of this year (Mar23) to the end of this year (Mar24) was (442.862 + 484.332 + 483.063 + 526.322 + 519.673) / 5 = $491.2504 Mil. Total Assets at the begining of this year (Mar23) was $442.9 Mil. Long-Term Debt & Capital Lease Obligation was $9.9 Mil. Total Current Assets was $270.6 Mil. Total Current Liabilities was $64.2 Mil. |
Net Income was -19.981 + 224.093 + 4.461 + -12.27 = $196.3 Mil. Revenue was 26.972 + 99.135 + 61.884 + 48.345 = $236.3 Mil. Gross Profit was 18.271 + 87.575 + 71.723 + 33.021 = $210.6 Mil. Average Total Assets from the begining of last year (Mar22) to the end of last year (Mar23) was (230.965 + 210.576 + 459.953 + 459.672 + 442.862) / 5 = $360.8056 Mil. Total Assets at the begining of last year (Mar22) was $231.0 Mil. Long-Term Debt & Capital Lease Obligation was $2.1 Mil. Total Current Assets was $231.5 Mil. Total Current Liabilities was $36.6 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kiniksa Pharmaceuticals's current Net Income (TTM) was 8.7.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kiniksa Pharmaceuticals's current Cash Flow from Operations (TTM) was 21.6.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Mar23) |
= | 8.65 | / | 442.862 | |
= | 0.01953204 |
ROA (Last Year) | = | Net Income | / | Total Assets (Mar22) |
= | 196.303 | / | 230.965 | |
= | 0.84992531 |
Kiniksa Pharmaceuticals's return on assets of this year was 0.01953204. Kiniksa Pharmaceuticals's return on assets of last year was 0.84992531.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Kiniksa Pharmaceuticals's current Net Income (TTM) was 8.7. Kiniksa Pharmaceuticals's current Cash Flow from Operations (TTM) was 21.6.
==> 21.6 > 8.7 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Mar24) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar23 to Mar24 |
= | 9.864 | / | 491.2504 | |
= | 0.02007937 |
Gearing (Last Year: Mar23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Mar22 to Mar23 |
= | 2.133 | / | 360.8056 | |
= | 0.00591177 |
Kiniksa Pharmaceuticals's gearing of this year was 0.02007937. Kiniksa Pharmaceuticals's gearing of last year was 0.00591177.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Mar24) | = | Total Current Assets | / | Total Current Liabilities |
= | 270.591 | / | 64.212 | |
= | 4.21402542 |
Current Ratio (Last Year: Mar23) | = | Total Current Assets | / | Total Current Liabilities |
= | 231.5 | / | 36.587 | |
= | 6.32738404 |
Kiniksa Pharmaceuticals's current ratio of this year was 4.21402542. Kiniksa Pharmaceuticals's current ratio of last year was 6.32738404.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Kiniksa Pharmaceuticals's number of shares in issue this year was 70.633. Kiniksa Pharmaceuticals's number of shares in issue last year was 69.752.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 252.305 | / | 301.772 | |
= | 0.83607823 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 210.59 | / | 236.336 | |
= | 0.89106188 |
Kiniksa Pharmaceuticals's gross margin of this year was 0.83607823. Kiniksa Pharmaceuticals's gross margin of last year was 0.89106188.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Mar23) |
= | 301.772 | / | 442.862 | |
= | 0.68141317 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Mar22) |
= | 236.336 | / | 230.965 | |
= | 1.02325461 |
Kiniksa Pharmaceuticals's asset turnover of this year was 0.68141317. Kiniksa Pharmaceuticals's asset turnover of last year was 1.02325461.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 1 | + | 1 | + | 0 | + | 1 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 | |
= | 3 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kiniksa Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Kiniksa Pharmaceuticals (NAS:KNSA) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael R Megna | officer: Chief Accounting Officer | 1050 HINGHAM STREET, ROCKLAND MA 02370 |
John Paolini | officer: Chief Medical Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Barry D Quart | director | C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549 |
Felix Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors (gp) Llc | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Eben Tessari | officer: Chief Business Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Arian Pano | officer: Chief Clinical Dev. Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Ross Moat | officer: Group VP & Rilonacept GM | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Sanj K Patel | director, 10 percent owner, officer: Chairman & CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas W. Beetham | 10 percent owner, officer: Chief Legal Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Mark Ragosa | officer: Interim CFO | C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-02-2022
By GuruFocusNews GuruFocusNews • 01-10-2022
By GuruFocusNews GuruFocusNews • 01-03-2022
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 05-02-2023
By PurpleRose PurpleRose • 08-03-2022
By GuruFocus Research GuruFocus Editor • 08-24-2021
By Value_Insider Value_Insider • 11-23-2022
By Marketwired Marketwired • 09-21-2021
By GuruFocusNews GuruFocusNews • 11-23-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.